CYP3A4 and gout: For approximately 30 years, benzbromarone has been used therapeutically for chronic gout and possesses cytotoxicity for hepatocellular carcinoma, which could be suppressed by CYP3A inhibitors, Nrf2 activator, and GSH precursor (45).